Business Wire

GLAS Completes Its Acquisition of Singaporean Corporate, Trust and Funds Service Provider, WATIGA

Share

The Global Loan Agency Services Group (“GLAS”) is delighted to confirm the successful completion of its acquisition of Watiga Trust and Watiga Asia (collectively, “Watiga”).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241215004425/en/

GLAS completes its acquisition of Singaporean corporate, trust and funds service provider, WATIGA (Graphic: Business Wire)

The transaction was first announced earlier this year in March pending regulatory approval from the Monetary Authority of Singapore (“MAS”) which was received in late November.

The integration will allow GLAS to offer its loan agency and trustee services to its local clients in Asia from a Singapore base. It will also provide Watiga’s clients with access to an enhanced, international service offering.

Watiga will be the second company acquired by GLAS this year, following French asset management and fiducie company Pristine, which became a GLAS company in April. Since then, GLAS and Pristine have jointly supported an enlarged client base, validating the strategic rationale of the transaction.

The acquisition of Watiga will expand the GLAS footprint across Asia Pacific, and the addition of the Watiga team will increase its team to over 60 professionals based locally in the region.

Watiga

Watiga is a corporate, trust and funds service provider.

Watiga Trust is a Licensed Trust Company, regulated by MAS and Approved Trustee for Collective Investment Schemes.

Offering a range of tailored trust, fiduciary and custodian services, Watiga Trust is a member of the Singapore Institute of Banking and Finance, the Singapore Trustees Association, the Singapore Venture and Private Capital Association and the Asia Pacific Loan Market Association.

Watiga Asia offers a full suite of fund, loan and company administration services and is a member of the Singapore Fund Administrators Association.

GLAS

GLAS has served the Asian market for several years, including roles in recent high-profile debt restructurings in China such as Sino Ocean, Evergrande and Sunac.

Following the completion of this acquisition, GLAS will support the expansion of the team’s local capabilities and ensure consistent client delivery globally, with GLAS’s existing APAC offices in Sydney, Melbourne and Brisbane providing additional operational support to Watiga.

GLAS Founders, Mia Drennan and Brian Carne, said:

“This has been another amazing year for GLAS. We are excited to be able to service our Asian clients locally in their time zone, and to work closely with Matt and the team to build out a wider selection of services and products which we can roll out globally.

This partnership bolsters the group’s comprehensive regulated coverage across APAC, the EU and the Americas, and gives our clients the opportunity to access our award-winning service and product offering to more clients than ever before.

This acquisition is another significant milestone on our global journey, and we are thrilled to be able to give our clients access to Watiga’s extensive knowledge, licensing and expertise through the GLAS network.”

Watiga Founder and Managing Director, Matt Richards, commented:

“Building WATIGA for the past thirteen years has been a rewarding journey of meeting market needs.

Our team is excited to continue this journey with GLAS, which brings fresh perspectives and new opportunities.

I believe GLAS's combination of technical expertise, financial infrastructure and their innovation mindset, all on a global scale, is beneficial and empowering for our clients, personnel, and stakeholders.”

About GLAS

GLAS was established in 2011 and is the premier independent, non-creditor, conflict-free provider of institutional debt administration services covering the global private and public credit markets.

GLAS, which services more than US$500bn of assets under administration, is headquartered in London and has operations in the US, France, Germany, Spain, the UAE and Australia.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241215004425/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release

- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least

Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release

-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization

Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release

Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou

Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release

Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi

Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release

Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye